Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "BENDAMUSTINE HYDROCHLORIDE FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"BENDAMUSTINE HYDROCHLORIDE FOR INJECTION"

OBTAINS APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that the anti-tumor drug "Bendamustine Hydrochloride for Injection" developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company, has obtained approval for drug registration granted by the National Medical Products Administration of the People's Republic of China. The product is applicable to the treatment of indolent B-cell non- Hodgkin's lymphoma that progresses during the rituximab or rituximab-containing treatment regimen or after the treatment. The product was filed as a Chemicals New Category 3 drug and is considered to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first of its kind that has obtained approval for drug registration in China. The approval for launch of this major product will further enrich and enhance the Group's hemato-oncology product line layout.

Bendamustine hydrochloride is a bifunctional alkylating agent with anti-tumor and cell-killing effects. As a new generation anticancer drug, bendamustine hydrochloride has the characteristics of low toxicity, high activity, broad anti-tumor spectrum, good tolerance by patients and being applicable for long-term use by patients. Bendamustine hydrochloride monotherapy or combination therapy has been designated as the first-line or second-line treatment option for a variety of hematological malignancies by European and American clinical guidelines.

Currently, only imported bendamustine hydrochloride for injection is available on the domestic market. The bendamustine hydrochloride for injection developed by the Group has the same prescription as the branded drug, with comparable efficacy. Its launch will reduce the cost of treatment for patients and reduce their financial burden for medication.

1

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 11 December 2019

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2